Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the JP Morgan Healthcare Conference

  Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the JP
                         Morgan Healthcare Conference

PR Newswire

SAN DIEGO, Calif., Dec. 24, 2012

SAN DIEGO, Calif., Dec. 24, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc.
(Nasdaq: OREX) today announced that management will present a company overview
at the JP Morgan Healthcare Conference in San Francisco. The presentation is
scheduled for Tuesday, January 8, 2013 at 10:30 a.m. Pacific Time. To listen
to the live webcast or a replay of the presentation, please visit the Investor
Relations section of the Company's Web site at www.orexigen.com. A replay will
be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment for the Light Study,
the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development WCG
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com